Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.32 (
phosphoenolpyruvate carboxykinase
)
4,204
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The cytosolic
phosphoenolpyruvate carboxykinase
(
PEPCK
) gene is expressed in multiple tissues and is regulated in a complex tissue-specific manner. To map the cis-acting DNA elements that direct this tissue-specific expression, we made transgenic mice containing truncated
PEPCK
-human growth hormone (hGH) fusion genes. The transgenes contained
PEPCK
promoter fragments with 5' endpoints at -2088, -888, -600, -402, and -207 bp, while the 3' endpoint was at +69 bp. Immunohistochemical analysis showed that the -2088 transgene was expressed in the correct cell types (hepatocytes, proximal tubular epithelium of the kidney, villar epithelium of the small intestine, epithelium of the colon, smooth muscle of the
vagina
and lungs, ductal epithelium of the sublingual gland, and white and brown adipocytes). Solution hybridization of hGH mRNA expressed from the transgenes indicated that white and brown fat-specific elements are located distally (-2088 to -888 bp) and that liver-, gut-, and kidney-specific elements are located proximally (-600 to +69 bp). However, elements outside of the region tested are necessary for the correct developmental pattern and level of
PEPCK
expression in kidney. Both the -2088 and -402 transgenes responded in a tissue-specific manner to dietary stimuli, and the -2088 transgene responded to glucocorticoid stimuli. Thus, different tissues utilize distinct cell-specific cis-acting elements to direct and regulate the
PEPCK
gene.
...
PMID:Tissue-specific, developmental, hormonal, and dietary regulation of rat phosphoenolpyruvate carboxykinase-human growth hormone fusion genes in transgenic mice. 154 85
We used immunohistochemical techniques to analyze the cell distribution of
phosphoenolpyruvate carboxykinase
(
PEPCK
) in adult and developing mouse tissues.
PEPCK
immunoreactivity was detected in many tissues, including some that had not been previously reported to contain
PEPCK
enzyme activity (bladder, stomach, ovary,
vagina
, parotid gland, submaxillary gland, and eye). In some multicellular tissues,
PEPCK
immunoreactivity was observed in multiple cell types. Several tissues (spleen, thyroid, and submaxillary gland) contained no detectable
PEPCK
immunoreactivity. During development,
PEPCK
immunoreactivity was associated with the developing nervous system and somites in 15-day embryos. At prenatal day 18,
PEPCK
immunoreactivity was detected only in the nervous system. At prenatal day 20,
PEPCK
immunoreactivity was observed in many of the tissues that contain
PEPCK
in the adult, with the exception of liver, lung, and stomach.
PEPCK
immunoreactivity was detected in liver at postnatal day 1, lung at postnatal day 7, and stomach after postnatal day 21. The only tissue in which
PEPCK
immunoreactivity decreased during development was the pancreas, where
PEPCK
immunoreactivity was detected at prenatal day 20 and was present until postnatal day 21. These results suggest that
PEPCK
expression is cell-type specific, more widespread than previously thought, and differentially expressed during development.
...
PMID:Immunohistochemical localization of phosphoenolpyruvate carboxykinase in adult and developing mouse tissues. 798 66